Glaser Weil Represents Alumni Capital in Equity Financing of NeuBase Therapeutics Inc.

Glaser Weil Partner Marc Indeglia and Associate Gabriel Kiss represented Alumni Capital Management in an equity financing of Pittsburgh-based biotech company NeuBase Therapeutics Inc. (NASDAQ: NBSE). Alumni Capital is a millennial alternative investment manager comprising alumni and students from various schools throughout the United States. The company aims to invest in top-tier innovative companies in the public markets.

Under the terms and conditions of the agreement, NeuBase has the right, but not the obligation, to sell to Alumni $3 million of its shares of common stock, which amount may increase at NeuBase’s option up to $10 million in shares, until December 28, 2024, subject to certain limitations.

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that “drug the genome.” NeuBase’s therapies are built on a proprietary platform called PATrOL™ that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with a novel delivery shuttle that overcomes many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The transaction closed on December 28, 2022.